Human papillomavirus vaccination completion rates among gynecological providers: an institutional retrospective review

References

• Satterwhite CL, Torrone E, Meites E, Dunne EF, Mahajan R, Ocfemia MC, Su J, Xu F, Weinstock H. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013;40(3):187–93. doi:10.1097/OLQ.0b013e318286bb53.
   PubMed Web of Science ®Google Scholar
• Impact of human papillomavirus vaccination on racial/ethnic disparities in vaccine-type human papillomavirus prevalence among. 14–26 year old females in the U.S. Vaccine. 2018;36(50):7682–88. doi:10.1016/j.vaccine.2018.10.075.
   PubMed Web of Science ®Google Scholar
• Viens LJ, Henley SJ, Markowitz LE, Thomas CC, Benard VB, et al. Trends in human papillomavirus-associated cancers- United States 1999–2015. MMWR Morb Mortal Wkly Rep. 2018;67(33):918–24. doi:10.15585/mmwr.mm6733a2.
   PubMed Web of Science ®Google Scholar
• Castle PE, Maza M, et al. Prophylactic HPV vaccination: past, present, and future. Epidemiology Infection. 2016; 144(3):449–68
   PubMed Web of Science ®Google Scholar
• Petrosky E, Bocchini JA, Hariri S, Chesson H, Curtis CR, Saraiya M, Unger ER, Markowitz LE. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64:300–04.
   PubMed Web of Science ®Google Scholar
• Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet. 2017;390(10108):2143–59. doi:10.1016/S0140-6736(17)31821-4.
   PubMed Web of Science ®Google Scholar
• U.S Food and Drug Administration. FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 yers old. October 5, 2018
   Google Scholar
• (CDC). National and state vaccination coverage among adolescents aged 13–17 years–united States, 2017. MMWR Morb Mortal Wkly Rep. 2018;67(33):909–17. doi:10.15585/mmwr.mm6733a1.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Immunization and Infectious Diseases. Healthy People 2020 Topics &Objectives 2012 May 18 http://www. Healthypeople.gov/2020/topicsobjectives2020/objectiveslist.aspx?topicid=23.
   Google Scholar
• Dawn HM, Benard V, Roland KB, Watson M, Liddon N, Stokley S. Barriers to human papillomavirus vaccination amon US adolescents: a synstematic review of the literature. JAMA Pediatr. 2014 Jan;168(1):76–82. doi:10.1001/jamapediatrics.2013.2752.
   PubMed Web of Science ®Google Scholar
• Unger Z, Maitra A, Kohn J, Devaskar S, Stern L, Patel A. Knowledge of HPV and HPV vaccine among women ages 19 to 26. Women’s Health Issues. 2015 Sep-Oct;25(5):458–62. doi:10.1016/j.whi.2015.06.003.
   PubMed Web of Science ®Google Scholar
• Barnard M, George P, Perryman ML, Wolff LA. Human papillomavirus (HPV) vaccine knowledge, attitudes, and uptake in college students: implications from the precaution adoption process model. PLoS One. 2017;12(8):e0182266. doi:10.1371/journal.pone.0182266.
   PubMed Web of Science ®Google Scholar
• Mills LA, Head KJ, Vanderpool RC. HPV vaccination among young adult women: a perspective from Appalachian Kentucky. Prev Chronic Dis. 2013;10:E17. doi:10.5888/pcd10.130016.
   PubMed Web of Science ®Google Scholar
• Sanderson M, Canedo JR, Khabele D, Fadden MK, Harris C, Beard K, Burress M, Pinkerton H, Jackson C, Mayo-Gamble T, et al. Pragmatic trial of an intervention to increase human papillomavirus vaccination in safety-net clinics. BMC Public Health. 2017 Feb 2;17(1):158. doi:10.1186/s12889-017-4094-1.
   PubMed Web of Science ®Google Scholar
• Simons HR, Unger ZD, Lopez PM, Kohn JE. Predictors of human papillomavirus vaccine completion among female and male vaccine initiators in family planning centers. Am J Public Health. 2015 Dec;105(12):2541–48. doi:10.2105/AJPH.2015.302834.
   PubMed Web of Science ®Google Scholar
• Okafor C, Hu X, Cook RL. Racial/ethnic disparities in HPV vaccine uptake among a sample of college women. J Racial Ethn Health Disparities. 2015 Sep;2(3):311–16. doi:10.1007/s40615-014-0074-7.
   PubMed Web of Science ®Google Scholar
• Perry R, Rankin K, Yu MC, Harwood B. Factors associated with human papillomavirus vaccination completion on a catch-up schedule. Obstet Gynecol. 2014 Jul;124(1):76–81. doi:10.1097/AOG.0000000000000319.
   PubMed Web of Science ®Google Scholar
• Hull PC, Williams EA, Khabele D, Dean C, Bond B, Sanderson M. HPV vaccine use among African American girls: qualitative formative research using a participatory social marketing approach. Gynecol Oncol. 2014 Mar;132(Suppl 1):S13–20. doi:10.1016/j.ygyno.2014.01.046.
   PubMed Web of Science ®Google Scholar
• Henrikson NB, Tuzzio L, Gilkey MB, McRee AL. “You’re never really off time”: healthcare providers’ interpretations of optimal timing for HPV vaccination. Preventative Med Rep. 2016 Dec;4:94–97. doi:10.1016/j.pmedr.2016.05.002.
   PubMedGoogle Scholar
• Hudson SM, Rondinelli J, Glenn BA, Preciado M, Chao C. Human papillomavirus vaccine series completion: qualitative information from providers within an integrated healthcare organization. Vaccine. 2016 Jun 24;34(30):3515–21. doi:10.1016/j.vaccine.2016.02.066.
   PubMed Web of Science ®Google Scholar
• McLean HQ, VanWormer JJ, Chow BDW, Birchmeier B, Vickers E, DeVries E, Meyer J, Moore J, McNeil MM, Stokley S, et al. Improving Human Papillomavirus Vaccine Use in an Integrated Health System: Impact of a Provider and Staff Intervention.
   Google Scholar
• Hall MT, Simms KT, Lew JB, Smith MA, Brotherton JM, Saville M, Frazer IH, Canfell K. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health. 2019; 4 (1): 19–27.
   Web of Science ®Google Scholar